AFMD Affimed N.V.

2.93
+0.26  (+10%)
Previous Close 2.67
Open 2.73
Price To Book 5.14
Market Cap 182,949,824
Shares 62,440,213
Volume 610,110
Short Ratio
Av. Daily Volume 527,749
Stock charts supplied by TradingView

NewsSee all news

  1. Affimed Reports Progress on Key Clinical Development Programs

      IND application submitted for first-in-human study of AFM24, a bispecific EGFR/CD16A innate cell engager for solid tumorsFDA clearance of IND for first clinical study of a stable complex of AFM13 pre-mixed with cord

  2. Affimed to Participate in Investor Conferences in September

      Heidelberg, Germany, August 28, 2019 - Affimed N.V. (NASDAQ:AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced its

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1b updated data at ICML June 22, 2019 noted ORR of 88% at highest dose, CR rates of 42%-46%.
AFM13 with Keytruda
Hodgkin Lymphoma - Cancer
Phase 2a ongoing.
AFM13
Hodgkin Lymphoma - Cancer
Phase 2 trial to be initiated 4Q 2019.
AFM13
CD30-positive peripheral T cell lymphoma (PTCL)
Phase 1 program terminated - noted May 22, 2019.
AFM11
Non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL)

Latest News

  1. Affimed Reports Progress on Key Clinical Development Programs

      IND application submitted for first-in-human study of AFM24, a bispecific EGFR/CD16A innate cell engager for solid tumorsFDA clearance of IND for first clinical study of a stable complex of AFM13 pre-mixed with cord

  2. Affimed to Participate in Investor Conferences in September

      Heidelberg, Germany, August 28, 2019 - Affimed N.V. (NASDAQ:AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced its